Table 1 Characteristics of study participants of newly diagnosed T2DM patients in UGCSH, January 2001–February 2019
Variable | Event (%) | Censored (%) | Total (n = 463) | Percentage |
|---|---|---|---|---|
Gender | ||||
Female | 45 (16.2) | 233 (83.8) | 278 | 60.04 |
Male | 32 (17.3) | 153 (82.7) | 185 | 39.96 |
Age | ||||
30–34 | 1 (16.7) | 5 (83.3) | 6 | 1.30 |
35–39 | 6 (19.4) | 25 (80.6) | 31 | 6.70 |
40–44 | 6 (12.0) | 44 (88.0) | 50 | 10.80 |
45–49 | 10 (11.9) | 74 (88.1) | 84 | 18.14 |
50–54 | 12 (15.6) | 65 (84.4) | 77 | 16.63 |
55–59 | 11 (14.7) | 64 (85.3) | 75 | 16.20 |
60–64 | 12 (19.7) | 49 (80.3) | 61 | 13.17 |
65–69 | 14 (31.1) | 31 (68.9) | 45 | 9.72 |
> 70 | 5 (14.7) | 29 (85.3) | 34 | 7.34 |
Duration of DM | ||||
0–4 | 15 (18.3) | 67 (81.7) | 82 | 17.71 |
5–9 | 35 (15.8) | 187 (84.2) | 222 | 47.95 |
10–14 | 22 (16.7) | 110 (83.3) | 132 | 28.51 |
> 14 | 5 (18.5) | 22 (83.4) | 27 | 5.83 |
Hypertension | ||||
Yes | 22 (20.6) | 85 (79.4) | 107 | 23.11 |
No | 55 (15.4) | 301 (84.6) | 356 | 76.89 |
Anemia | ||||
Yes | 22 (59.5) | 15 (40.5) | 37 | 7.99 |
No | 62 (14.5) | 364 (85.5) | 426 | 92.01 |
Other DM complication | ||||
Yes | 43 (24.2) | 135 (75.8) | 178 | 38.44 |
No | 34 (11.9) | 251 (88.1) | 285 | 61.56 |
Baseline medication | ||||
Dietary modification | 4 (13.8) | 25 (86.2) | 29 | 6.26 |
One oral agent | 47 (15.9) | 249 (84.1) | 296 | 63.93 |
> 1 Oral agent | 17 (21.5) | 62 (78.5) | 79 | 17.06 |
Insulin | 9 (15.3) | 50 (84.7) | 59 | 12.74 |
SBP | ||||
≤ 140 | 62 (16.5) | 313 (83.5) | 375 | 80.99 |
> 140 | 15 (17.1) | 73 (82.9) | 88 | 19.01 |
DBP | ||||
≤ 90 | 69 (16.7) | 344 (83.3) | 413 | 89.20 |
> 90 | 8 (16.0) | 42 (84.0) | 50 | 10.80 |